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Aims Although acute venous thrombo-embolism (VTE) often afflicts patients with advanced age, the predictors of
in-hospital mortality for elderly VTE patients are unknown.
Methods
and results
Among 1247 consecutive patients with acute VTE from the prospective SWIss Venous ThromboEmbolism Registry
(SWIVTER), 644 (52%) were elderly (≥65 years of age). In comparison to younger patients, the elderly more often
had pulmonary embolism (PE) (60 vs. 42%; P, 0.001), cancer (30 vs. 20%; P, 0.001), chronic lung disease (14 vs.
8%; P ¼ 0.001), and congestive heart failure (12 vs. 2%; P, 0.001). Elderly VTE patients were more often hospitalized
(75 vs. 52%; P, 0.001), and there was no difference in the use of thrombolysis, catheter intervention, or surgical
embolectomy between the elderly and younger PE patients (5 vs. 6%; P ¼ 0.54), despite a trend towards a higher
rate of massive PE in the elderly (8 vs. 4%; P ¼ 0.07). The overall in-hospital mortality rate was 6.6% in the
elderly vs. 3.2% in the younger VTE patients (P ¼ 0.033). Cancer was associated with in-hospital death both in
the elderly [hazard ratio (HR) 4.91, 95% confidence interval (CI) 2.32–10.38; P, 0.001] and in the younger patients
(HR 4.90, 95% CI 1.37–17.59; P ¼ 0.015); massive PE was a predictor of in-hospital death in the elderly only (HR
3.77, 95% CI 1.63–8.74; P ¼ 0.002).
Conclusion Elderly patients had more serious VTE than younger patients, and massive PE was particularly life-threatening in the
elderly.
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Introduction
The incidence of venous thrombo-embolism (VTE), comprising
deep vein thrombosis (DVT) and pulmonary embolism (PE),
increases exponentially with advancing age.1 The elderly, for
whom the cut-off point of 65 years was adopted by the Inter-
national Conference on Harmonisation of Technical Requirements
of Pharmaceuticals for Human Use (ICH) E7 guideline on geriatric
patients, represent the fastest growing demographic segment of
the patient population in the industrial world.2 High incidences
of concomitant diseases and co-medications, impaired hepatic or
renal function, and changes in pharmacokinetic and pharmacody-
namic profiles make elderly patients especially vulnerable. The
current consensus guidelines of the American College of Chest
Physicians (ACCP) do not issue specific recommendations
devoted to the acute management of elderly VTE patients.3
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Intermediate and long-term survival of elderly VTE patients is
poor, and the elderly are especially prone to bleeding complica-
tions from anticoagulation or reperfusion treatment.4–8 It is
unknown whether differences in VTE severity exist between the
elderly and younger patients, and whether VTE severity impacts
on short-term clinical outcomes. We also aimed to explore the
clinical predictors of early mortality in elderly hospitalized patients
with acute objectively confirmed VTE.
Methods
Patients
The prospective SWIss Venous ThromboEmbolism Registry
(SWIVTER) enrolled 1247 consecutive patients with acute DVT or
PE from 4 academic and 14 non-academic acute care hospitals in Switz-
erland from January 2009 to May 2010. Inclusion criteria were age ≥18
years and objectively confirmed acute VTE event, by compression
ultrasound or phlebography in the case of DVT, and by
contrast-enhanced chest computed tomography, ventilation perfusion
scan, or conventional pulmonary angiography in the case of PE. There
were no exclusion criteria. Eligible patients were enrolled during clin-
ical inpatient or outpatient visits at participating hospitals. SWIVTER
issued no recommendations on VTE diagnosis or management. The
study was approved by the local Ethics Committees of the participating
hospitals.
Data, definitions, and statistical analysis
Anonymous data on patient demographics, co-morbidities, localization
of VTE, risk factors for VTE and bleeding, management, and clinical
outcomes such as in-hospital mortality, recurrent VTE, and bleeding
requiring treatment were collected in a standardized case report
form (CRF). Data were directly entered into the electronic CRF by
the physician in charge of the patient’s care or by a study physician
or a study nurse and then securely transmitted to a central database
monitored by an independent data coordinating centre (La Volta Sta-
tistics, Zurich, Switzerland).
Elderly age was defined as an age of 65 or more years. Massive PE
was predefined as PE with systolic arterial hypotension (blood pres-
sure levels of ,90 mmHg) or as PE requiring cardiopulmonary resus-
citation or the administration of catecholamines.9 Provoked VTE was
defined as thrombosis associated with surgery, hospitalization, immo-
bilization for more than 3 days, oestrogen therapy, pregnancy, or pro-
longed travel of more than 5 h, all within 30 days prior to VTE
diagnosis.3 Reperfusion therapy for PE included systemic thrombolysis,
catheter intervention with or without thrombolysis, or surgical embol-
ectomy. Reperfusion therapy for DVT included catheter-directed
thrombolysis, catheter intervention with or without thrombolysis, or
surgical thrombectomy. Recurrent VTE was defined as symptomatic
non-fatal PE and/or symptomatic DVT after the initial VTE diagnosis.
Group comparisons for continuous variables with a normal distribu-
tion were performed using the t-test and the data were described as
means with standard deviations (SD), group comparisons for continu-
ous variables with a skewed distribution were performed using the
Wilcoxon rank-sum test and the data were presented as median
values with inter-quartile ranges (IQRs), and group comparisons for
discrete variables were performed using the x2 or Fisher exact test
and the data were presented as frequencies and percentages.
For identifying clinical factors associated with in-hospital mortality,
univariate Cox’s regression analysis reporting hazard ratios (HRs)
with 95% confidence intervals (CIs) was performed. All reported
P-values are two-tailed. The data were analysed using STATA 10
software (STATACorp LP, College Station, TX, USA).
Results
Patient characteristics
Overall, 1247 patients were enrolled; 644 (52%) were elderly and
603 (48%) younger than 65 years of age. In comparison to younger
patients, the elderly were more often hospitalized at the time of
VTE diagnosis or immobilized for more than 3 days, more fre-
quently had an acute infection, acute respiratory or heart failure,
diabetes, chronic respiratory or heart disease, renal failure, and a
history of stroke, but less often were obese and less frequently
had recent surgery or trauma (Table 1).
The elderly more often had acute PE when compared with the
younger patients (60 vs. 42%; P, 0.001), whereas they less often
had first isolated distal DVT (11 vs. 18%; P ¼ 0.001) and upper-
extremity DVT (5 vs. 8%; P ¼ 0.011). In comparison to younger
patients, the elderly more frequently had cancer-associated VTE
(30 vs. 20%; P, 0.001) and less often had provoked VTE (38 vs.
45%; P ¼ 0.009). Among patients who were diagnosed during an
outpatient visit, the elderly more often had acute PE than
younger patients (54 vs. 37%; P, 0.001). Among patients who
were diagnosed during an inpatient visit, the elderly more often
had acute PE when compared with the younger patients (67 vs.
56%; P ¼ 0.013). Among patients who were treated on an out-
patient basis, acute PE was similarly often present in the elderly
and younger patients (21 vs. 18%; P ¼ 0.46). Among patients
who were hospitalized after VTE diagnosis, the elderly more
often had acute PE when compared with the younger patients
(74 vs. 65%; P ¼ 0.007).
Among patients with acute PE, there was a trend towards a
higher rate of massive PE in the elderly vs. younger patients, and
the elderly more frequently had positive cardiac biomarkers,
troponin T or I or (N-terminal pro) B-type natriuretic peptide
(BNP), oxygen saturation in room air below 90%, dyspnoea, and
a high simplified pulmonary embolism severity index (sPESI)
when compared with the younger patients (Table 2). Among PE
patients ≤80 years of age, patients between 65 and 80 years of
age more often had a high sPESI than patients below 65 years of
age (69 vs. 49%; P, 0.001). Among patients with DVT alone,
DVT of the inferior vena cava (IVC) or the iliac veins was similarly
often present in both age groups (18 vs. 17%; P ¼ 0.80). Among
patients with cancer-associated VTE, younger patients more fre-
quently had metastatic disease, recent chemotherapy, or surgery
(Table 1).
Initial and long-term treatment of VTE
Overall, 75% of the elderly and 52% of younger VTE patients were
hospitalized (Table 1). In total, the median duration of hospital stay
was 11 (IQR 7–20) days; it was 12 (7–22) days in the elderly and
10 (5–19) days in the younger patients (P ¼ 0.022). Among the
644 patients with acute PE, elderly patients were more often hos-
pitalized than younger patients (92 vs. 80%; P, 0.001). Among the
603 patients with acute DVT alone, elderly patients were more
often treated on an inpatient basis than younger patients (50 vs.
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32%; P, 0.001). Among VTE patients who were diagnosed during
an outpatient visit, the elderly were more often hospitalized when
compared with the younger patients (55 vs. 34%; P, 0.001).
Among PE patients who were diagnosed during an outpatient
visit, the elderly were more often hospitalized when compared
with the younger patients (83 vs. 68%; P ¼ 0.001).
There was no difference in the use of reperfusion therapy, in-
cluding systemic thrombolysis, catheter intervention, and surgical
thrombectomy between the elderly and younger PE patients
(Table 2). There was also no difference in the use of reperfusion
therapy (31 vs. 20%; P ¼ 0.50), including systemic thrombolysis
(21 vs. 20%; P ¼ 0.96), catheter intervention (7 vs. 0%; P ¼ 0.39),
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Table 1 Patient characteristics, co-morbidities, and venous thrombo-embolism therapy
Total (n5 1247) Age ≥65 (n5 644) Age <65 (n5 603) P-value
Demographics
Age (years), mean+ SD 61+18 76+7 46+13 ,0.001
Women, n (%) 605 (48.5) 321 (49.8) 284 (47.1) 0.33
Inpatient at the time of diagnosis, n (%) 478 (38.3) 304 (47.2) 174 (28.9) ,0.001
Prior hospitalization, n (%) 332 (26.6) 179 (27.8) 153 (25.4) 0.33
Co-morbidities
Cancer, n (%) 315 (25.3) 192 (29.8) 123 (20.4) ,0.001
Metastatic disease, n (%) 179 (65.1) 97 (59.9) 82 (72.6) 0.030
Recent cancer surgery, n (%) 83 (27.8) 37 (20.9) 46 (37.7) 0.001
Recent chemotherapy, n (%) 154 (52.2) 77 (44.0) 77 (64.2) 0.001
Prior VTE, n (%) 288 (23.1) 147 (22.8) 141 (23.4) 0.82
Bed rest for .3 days, n (%) 231 (18.5) 146 (22.7) 85 (14.1) ,0.001
Obesity, n (%) 174 (14.0) 76 (11.8) 98 (16.3) 0.023
Surgery, n (%) 170 (13.6) 74 (11.5) 96 (15.9) 0.023
Varicosis, n (%) 164 (13.2) 102 (15.8) 62 (10.3) 0.004
Acute infection/sepsis n (%) 148 (11.9) 92 (14.3) 56 (9.3) 0.006
Chronic lung disease, n (%) 140 (11.2) 91 (14.1) 49 (8.1) 0.001
Diabetes, n (%) 114 (9.1) 90 (14.0) 24 (4.0) ,0.001
Ongoing chemotherapy, n (%) 114 (9.1) 59 (9.2) 55 (9.1) 0.98
Trauma/fracture n (%) 91 (7.3) 34 (5.3) 57 (9.5) 0.005
Renal failure, n (%) 89 (7.1) 61 (9.5) 28 (4.6) 0.001
Inflammatory/rheumatic disease, n (%) 89 (7.1) 50 (7.8) 39 (6.5) 0.37
Acute respiratory failure, n (%) 83 (6.7) 59 (9.2) 24 (4.0) ,0.001
Congestive heart failure, n (%) 81 (6.5) 71 (11.0) 10 (1.7) ,0.001
ICU admission, n (%) 69 (5.5) 41 (6.4) 28 (4.6) 0.18
History of stroke/TIA, n (%) 67 (5.4) 61 (9.5) 6 (1.0) ,0.001
Bleeding requiring treatment within 30 days prior to VTE diagnosis,
n (%)
60 (4.8) 34 (5.3) 26 (4.3) 0.43
Acute heart failure, n (%) 37 (3.0) 31 (4.8) 6 (1.0) ,0.001
VTE therapy
Inpatient therapy, n (%) 800 (64.2) 484 (75.2) 316 (52.4) ,0.001
Compression therapy, n (%) 1’031 (82.7) 548 (85.1) 483 (80.1) 0.020
IVC filter, n (%) 20 (1.6) 12 (1.9) 8 (1.3) 0.45
UFH or LMWH, n (%) 1’200 (96.2) 619 (96.1) 581 (96.4) 0.83
Vitamin K antagonist, n (%) 970 (77.8) 509 (79.0) 461 (76.5) 0.27
Planned duration of anticoagulation
≤3 months, n (%) 198 (15.9) 85 (13.2) 113 (18.7) 0.007
.3–6 months, n (%) 483 (38.7) 237 (36.8) 246 (40.8) 0.15
.6–12 months, n (%) 243 (19.5) 128 (19.9) 115 (19.1) 0.72
.12 months or indefinitely, n (%) 323 (25.9) 194 (30.1) 129 (21.4) ,0.001
VTE, venous thrombo-embolism; ICU, intensive care unit; TIA, transient ischemic attack; IVC, inferior vena cava; UFH, unfractionated heparin; LMWH, low-molecular-weight
heparin.
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and surgical thrombectomy (7 vs. 0%; P ¼ 0.39) between the
elderly and younger patients with massive PE. Reperfusion
therapy (0.8 vs. 4.6%; P ¼ 0.007), including catheter-directed
thrombolysis (0.4 vs. 3.5%; P ¼ 0.011) and surgical thrombectomy
(0.8 vs. 2.5%; P ¼ 0.10), was less often administered in the elderly
when compared with the younger patients with DVT alone.
Overall, the elderly more frequently received antithrombotic
therapy with unfractionated heparin (31 vs. 18%; P, 0.001) and
less often with low-molecular-weight heparin (80 vs. 88%;
P, 0.001); twice-daily regimens were prescribed more frequently
in the elderly (27 vs. 18%; P, 0.001). Mechanical therapy with vas-
cular compression stockings or bandages was more often pre-
scribed to elderly than to younger patients; there was no
difference in the use of IVC filters between both age groups
(Table 1).
In-hospital clinical outcomes
The overall rate of in-hospital mortality was 5.3%; this rate was
greater in the elderly when compared with the younger patients
(6.6 vs. 3.2%; P ¼ 0.033; Figure 1). In total, the proportion of
patients with in-hospital recurrent non-fatal VTE was 2.3%; it
was 1.5% in the elderly and 3.5% in the younger patients
(P ¼ 0.06). The overall rate of in-hospital bleeding requiring treat-
ment was 5.1%; this rate was greater in the elderly when compared
with the younger patients (6.6 vs. 2.9%; P ¼ 0.018).
In hospitalized patients, cancer (HR 5.15, 95% CI 2.71–9.82;
P, 0.001), massive PE (HR 4.25, 95% CI 1.96–9.20; P, 0.001),
hypoxia (HR 4.17, 95% CI 2.10–8.25; P, 0.001), chronic lung
disease (HR 3.16, 95% CI 1.68–5.96; P, 0.001), tachycardia (HR
2.52, 95% CI 1.36–4.67; P ¼ 0.003), and an increasing age (HR
1.04, 95% CI 1.02–1.07; P ¼ 0.001) were univariate predictors of
in-hospital death. In elderly hospitalized VTE patients, cancer,
massive PE, hypoxia, and chronic lung disease were univariately
associated with in-hospital death (Table 3). In younger hospitalized
VTE patients, hypoxia, tachycardia, and cancer were univariate pre-
dictors of in-hospital death.
Discussion
In the SWIVTER, elderly patients over 65 years of age had more
serious VTE than younger patients. First, PE occurred more fre-
quently in the elderly when compared with the younger VTE
patients. In addition, PE severity was pronounced in the elderly
as evidenced by higher rates of an increased sPESI,10 of increased
cardiac biomarkers, and a trend towards a higher rate of massive
PE. Secondly, massive PE was particularly life-threatening in the
elderly. Finally, potentially life-saving reperfusion treatment was
used in less than one-third of patients with massive PE from
both age groups. Overall, our data suggest but do not prove that
there might be an underuse of reperfusion therapy among patients
with massive PE. High rates of co-morbidities and an increased risk
of bleeding may partly explain the omission of reperfusion therapy,
particularly in elderly patients with massive PE. However, an
increased risk of bleeding may prohibit the administration of sys-
temic thrombolysis but not necessarily a catheter intervention,
with or without the use of catheter-directed thrombolysis, or sur-
gical embolectomy.
The clinical manifestation of VTE between the elderly and
younger patients differed substantially in SWIVTER; the elderly
more often had cancer and less frequently had provoked VTE
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Table 2 Patient characteristics and reperfusion therapy in patients with pulmonary embolism
Total (n5 644) Age ≥65 (n5 389) Age <65 (n 5 255) P-value
Dyspnoea, n (%) 527 (82.5) 331 (85.5) 196 (77.8) 0.012
Positive (N-terminal pro) BNP,a n (%) 150/249 (60.2) 121/180 (67.2) 29/69 (42.0) ,0.001
Right heart strain by ECG,b n (%) 233/499 (46.7) 149/305 (48.9) 84/194 (43.3) 0.23
Concomitant DVT, n (%) 227 (35.3) 126 (32.4) 101 (39.6) 0.06
Oxygen saturation in room air ,90%, n (%) 174/577 (30.2) 124/340 (36.5) 50/237 (21.1) ,0.001
Positive troponin T or I,a n (%) 99/387 (25.6) 79/251 (31.5) 20/136 (14.7) ,0.001
Heart rate ≥110 b.p.m., n (%) 158/619 (25.5) 100/369 (27.1) 58/250 (23.2) 0.28
Syncope, n (%) 64 (10.0) 44 (11.3) 20 (7.9) 0.16
Massive PE,c n (%) 39 (6.1) 29 (7.5) 10 (3.9) 0.07
High sPESI,d n (%) 430 (66.8) 304 (78.2) 126 (49.4) ,0.001
Reperfusion therapy, n (%) 36 (5.6) 20 (5.1) 16 (6.3) 0.54
Systemic thrombolysis, n (%) 21 (3.3) 13 (3.3) 8 (3.1) 0.89
Catheter intervention, n (%) 10 (1.6) 5 (1.3) 5 (2.0) 0.50
Surgical thrombectomy, n (%) 9 (1.4) 3 (0.8) 6 (2.4) 0.09
aA positive biomarker test result was defined as a quantitative biomarker level above the manufacturer’s assay threshold.
bRight heart strain by electrocardiography (ECG) was defined as the presence of at least one of the following signs: sinus tachycardia, incomplete or complete right bundle branch
block, SI-QIII type, or negative T-waves in V2, V3, or V4 within 24 h of VTE diagnosis.
cMassive PE was defined as PE with systolic arterial hypotension (systolic blood pressure of ,90 mmHg) or as PE requiring cardiopulmonary resuscitation or the administration of
catecholamines.
dA high simplified pulmonary embolism severity index (sPESI) was defined as the presence of at least one of the following criteria: age .80 years, systolic systemic pressure
,100 mmHg, heart rate .110 b.p.m., oxygen saturation ,90%, cancer, heart failure, and chronic lung disease.9
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and first isolated distal or upper-extremity DVT when compared
with the younger patients. The higher incidence of cancer-
associated VTE and the lower incidence of upper-extremity DVT
in the elderly in our study are consistent with the results of the
Worcester Venous Thromboembolism Study11 and previous regis-
tries.12,13 The finding of a lower proportion of provoked VTE in
the elderly vs. younger patients contrasts with the Worcester
Venous Thromboembolism Study.11
When compared with a recent review of studies of elderly
patients with acute PE, the most common clinical PE symptoms
in our study were dyspnoea (86 vs. 59–92%) and tachycardia
(27 vs. 29–76%).14 The overall proportion of massive PE in
SWIVTER and in the International Cooperative Pulmonary
Embolism Registry (ICOPER) was similar (6 vs. 5%), and both regis-
tries reported that more than two-thirds of patients with massive
PE did not receive reperfusion therapy.9
Our study offers important insights regarding the relationship
between age and management of unselected patients with acute
VTE. Two-thirds of the elderly and half of the younger patients
were treated in a hospital setting, an observation that likely corre-
sponds to higher rates of PE and co-morbidities in the elderly. The
elderly more frequently received intravenous unfractionated
heparin as an initial antithrombotic agent, probably because of a
higher rate of massive PE, renal failure, or other bleeding risk
factors. When compared with younger patients, the rate of reper-
fusion therapy for acute DVT was lower in the elderly patients
(1 vs. 5%), reflecting an increased risk of bleeding complications
and a shorter life expectancy in the elderly.
Elderly VTE patients had a higher rate of early death when com-
pared with younger VTE patients, a finding that confirms the
results of ICOPER with an age of .70 years as an independent
predictor of 3-month mortality.15 The rate of bleeding complica-
tions exceeded the rate of recurrent VTE among elderly patients
in our study (in-hospital bleeding requiring medical attention:
6.5% vs. in-hospital VTE recurrence: 1.4%) and in the Registro
Figure 1 In-hospital mortality and bleeding requiring treatment (n ¼ 800).
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Table 3 Clinical factors univariately associated with
in-hospital mortality
Factor HR 95% CI P-value
Patients ≥65 years of age
Cancer 4.91 2.32–10.38 ,0.001
Massive PE 3.77 1.63–8.74 0.002
Oxygen saturation in room
air ,90%
3.58 1.65–7.77 0.001
Chronic lung disease 2.89 1.42–5.85 0.003
Heart rate ≥110 b.p.m. 1.98 0.97–4.05 0.06
Congestive heart failure 1.32 0.54–3.22 0.54
Recurrent VTE 0.23 0.05–0.96 0.044
Patients ,65 years of age
Oxygen saturation in room
air ,90%
6.90 1.34–35.69 0.021
Heart rate ≥110 b.p.m. 5.82 1.53–22.14 0.010
Cancer 4.90 1.37–17.59 0.015
Congestive heart failure 4.42 0.55–35.41 0.16
Massive PE 4.02 0.49–32.68 0.19
Chronic lung disease 3.31 0.67–16.38 0.14
Recurrent VTE 1.79 0.49–6.60 0.38
HR, hazard ratio; CI, confidence interval; PE, pulmonary embolism; VTE, venous
thrombo-embolism.
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Informatizado de la Enfermedad TromboEmbo´lica (RIETE) (major
bleeding at 3 months: 3.4% vs. VTE recurrence at 3 months:
2.1%).16 Similar results were also observed in the Worcester
Venous Thromboembolism Study.11
The main strength of our study is the multicentric prospective
inclusion of unselected VTE patients in a real-world setting that
provides a representative picture of the age distribution in patients
with acute VTE. A weakness of the study is that no systematic
follow-up beyond hospital discharge was obtained. The high pro-
portion of PE patients in our study population of hospital-managed
VTE patients reflects that many DVT patients were likely not
enrolled in SWIVTER because in Switzerland, DVT patients are
increasingly being managed on an outpatient basis from private
practices.17 Finally, our findings may not necessarily be valid in
other countries; particularly, the novel finding of an increased
VTE severity in the elderly requires confirmation from other
national or international surveys.
In conclusion, elderly patients had more serious VTE than
younger patients, and massive PE was particularly life-threatening
in the elderly. Future PE management studies should consider
the inclusion of elderly patients where clinical benefit from reper-
fusion therapy, including catheter-based interventions with or
without thrombolysis, may potentially be present.
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